26
|
Rehman S, Dhatariya KK. METASTATIC HÜRTHLE CELL CARCINOMA PRESENTING WITH LOW FREE THYROXINE, SEVERE HYPERCALCEMIA AND SPURIOUS GROWTH HORMONE PRODUCTION. AACE Clin Case Rep 2020; 5:e204-e209. [PMID: 31967035 DOI: 10.4158/accr-2018-0440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2018] [Accepted: 12/19/2018] [Indexed: 11/15/2022] Open
Abstract
Objective Hürthle cell tumors constitute about 5% of thyroid neoplasms. They have malignant potential, behaving very aggressively compared to other differentiated thyroid cancers. The objective of this case report is to describe a case of a Hürthle cell carcinoma with a single large metastasis in the liver presenting almost 17 years after hemithyroidectomy. We highlight the difficulties in making a histologic diagnosis and the unpredictable nature of this cancer. Methods The patient history and biochemistry were detailed. Thyroid function tests analyzed on multiple platforms (single-photon emission computed tomography, dynamic magnetic resonance imaging, technetium-99m bone scan, and radioactive iodine) were used to aid biochemical and radiologic diagnosis. Results The patient's thyroid function test showed persistently low free thyroxine concentrations with normal thyroid stimulating hormone and free triiodothyronine, suggesting rapid deiodination in the context of a large liver lesion. Radiologic and morphologic appearances of the liver lesion led to an initial misdiagnosis of primary hepato-cellular carcinoma, revised to metastatic Hürthle cell carcinoma after positive immunochemistry. Nonparathyroid hormone-related intractable hypercalcemia of malignancy with an unusual pattern of elevated 1,25-dihydroxyvitamin D and raised fibroblast growth factor 23 concentrations culminated in his demise. Conclusions In Hürthle cell carcinomas treated with partial thyroidectomy, subsequent abnormal thyroid functions tests may herald a more sinister underlying diagnosis. The management of Hürthle cell carcinoma relies heavily on the initial histology results. Histologic diagnosis should be sought earlier in abnormal and suspicious distant masses. Malignant hypercalcemia poses a great challenge in delayed presentations and can prove resistant to conventional treatments.
Collapse
|
27
|
Rehman S, Almessiere MA, Khan FA, Korkmaz AD, Tashkandi N, Slimani Y, Baykal A. Synthesis and biological characterization of Mn 0.5Zn 0.5Eu xDy xFe 1.8-2xO 4 nanoparticles by sonochemical approach. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2019; 109:110534. [PMID: 32228890 DOI: 10.1016/j.msec.2019.110534] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Revised: 12/03/2019] [Accepted: 12/06/2019] [Indexed: 02/07/2023]
Abstract
Metallic nanoparticles (NPs) possess unique properties which makes them attractive candidates for various applications especially in field of experimental medicine and drug delivery. Many approaches were developed to synthesize divers and customized metallic NPs that can be useful in many areas such as, experimental medicine, drug design, drug delivery, electrical and electronic engineering, electrochemical sensors, and biochemical sensors. Among different metallic nanoparticles, manganese (Mn) NPs are the most prominent materials, in the present study, we have synthetized unique Mn0.5Zn0.5DyxEuxFe1.8-2xO4 NPs by using ultrasonication method (x ≤ 0.1). The structure, and surface morphology of Mn0.5Zn0.5DyxEuxFe1.8-2xO4 NPs was characterized by XRD, SEM, TEM and EDX methods. We have examined the biological effects of Mn0.5Zn0.5DyxEuxFe1.8-2xO4 NPs on both normal (HEK-293) and cancerous (HCT-116) cells. We have found that the treatment of Mn0.5Zn0.5DyxEuxFe1.8-2xO4 NPs post 48 h, showed significant decline in cancer cells population as revealed by MTT assay. The IC50 value of Mn0.5Zn0.5DyxEuxFe1.8-2xO4 NPs was ranged between (2.35 μg/mL to 2.33 μg/mL). To check the specificity of the actions, we found that the treatment of Mn0.5Zn0.5DyxEuxFe1.8-2xO4 NPs did not produce any effects on the normal cells, which suggest that Mn0.5Zn0.5DyxEuxFe1.8-2xO4 NPs selectively targeted the cancerous cells. The anti-bacterial properties of Mn0.5Zn0.5DyxEuxFe1.8-2xO4 NPs were also evaluated by MIC and MBC assays. We suggest that Mn0.5Zn0.5DyxEuxFe1.8-2xO4 NPs produced by sonochemical method possess potential anti-cancer and anti-bacterial capabilities.
Collapse
|
28
|
Rehman S, Nabi B, Zafar A, Baboota S, Ali J. Intranasal delivery of mucoadhesive nanocarriers: a viable option for Parkinson's disease treatment? Expert Opin Drug Deliv 2019; 16:1355-1366. [PMID: 31663382 DOI: 10.1080/17425247.2019.1684895] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Introduction: Intranasal drug delivery is a largely unexplored, promising approach for the treatment of various neurological disorders. However, due to the challenging constraints available in the pathway of nose-to-brain delivery, finding an effective treatment for Parkinsonism is still an impending mission for research workers. This warrants development of novel treatment alternatives for Parkinson's disease (PD). Intranasal delivery of mucoadhesive nanocarriers is one such novel approach which might help in curbing the glitches associated with the currently available therapy.Areas covered: This review summarizes the evidences supporting nose-to-brain delivery of polymer-based mucoadhesive nanocarriers for the treatment of PD. A concise insight into the lipid-based mucoadhesive nanocarriers has also been presented. The recent researches have been compiled pertaining to the use of mucoadhesive nanocarrriers for improving the treatment outcomes of PD via intranasal drug delivery.Expert opinion: Although the use of nanocarrier-based strategies for site-specific delivery via intranasal route has proven effective, the magnitude of improvement remains moderate resulting in limited translation from industry to the market. Comprehensive understanding of the mucoadhesive polymer, its characteristics and mechanisms involved for an effective nose-to-brain uptake of the drug is a promising avenue to develop novel formulations for effective management of Parkinson disease.
Collapse
|
29
|
Thein K, Jahan N, Tun A, Sultan A, Swarup S, Mogollon-Duffo F, Yendala R, Quirch M, Htut T, D’Cunha N, Rehman S, Hardwicke F, Awasthi S, Tijani L. MA03.07 First-Line Atezolizumab Chemoimmunotherapy in Advanced Non-Squamous NSCLC Patients Harboring EGFR/ALK Genetic Alterations. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.516] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Thein K, Mogollon-Duffo F, Swarup S, Sultan A, Yendala R, Jahan N, Quirch M, Ball S, Htut TW, D’Cunha N, Rehman S, Hardwicke F, Awasthi S, Tijani L. Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz249.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Thein K, Jahan N, Sultan A, Swarup S, Tun A, Yendala R, Ball S, Hlaing P, Htut T, Rehman S, D’Cunha N, Hardwicke F, Tijani L, Awasthi S. P1.04-78 Efficacy of Checkpoint Inhibitors in Combination with Chemotherapy for First-Line Treatment of Advanced Non-Squamous NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
32
|
Jahan N, Thein K, Sultan A, Swarup S, Mogollon-Duffo F, Adhikari N, Arevalo M, Htut T, Naing T, D’Cunha N, Rehman S, Hardwicke F, Tijani L. P2.04-46 Tolerability and Treatment-Related Adverse Events of Upfront Pembrolizumab Combination Regimens in Advanced NSCLC Patients. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Swarup S, Thein K, Sultan A, Jahan N, Quirch M, Meda S, Htut T, Adhikari N, Hlaing P, Dash A, Tun A, Rehman S, Hardwicke F, Tijani L. P1.01-78 Treatment-Related Adverse Events in Patients with Advanced NSCLC Treated with First-Line Atezolizumab Chemoimmunotherapy. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
34
|
Sultan A, Thein K, Swarup S, Jahan N, Tun A, Meda S, Arevalo M, Naing T, Htut T, D’Cunha N, Awasthi S, Rehman S, Tijani L, Hardwicke F. P2.04-09 Immune-Related Adverse Events in Advanced Non-Squamous NSCLC Patients Treated with Upfront Checkpoint Inhibitors Combination. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
Simeone X, Iorio M, Siebert D, Rehman S, Schnürch M, Mihovilovic M, Ernst M. Defined concatenated α6α1β3γ2 GABAA receptor constructs reveal dual action of pyrazoloquinolinone allosteric modulators. Bioorg Med Chem 2019; 27:3167-3178. [DOI: 10.1016/j.bmc.2019.06.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Revised: 05/08/2019] [Accepted: 06/03/2019] [Indexed: 12/20/2022]
|
36
|
Nabi B, Rehman S, Baboota S, Ali J. Insights on Oral Drug Delivery of Lipid Nanocarriers: a Win-Win Solution for Augmenting Bioavailability of Antiretroviral Drugs. AAPS PharmSciTech 2019; 20:60. [PMID: 30623263 DOI: 10.1208/s12249-018-1284-9] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2018] [Accepted: 12/18/2018] [Indexed: 02/06/2023] Open
Abstract
The therapeutic functionality of innumerable antiretroviral drugs is supposedly obscured owing to their low metabolic stability in the gastrointestinal tract and poor solubilization property leading to poor oral bioavailability. Dictated by such needs, lipid-based formulations could be tailored using nanotechnology which would be instrumental in ameliorating the attributes of such drugs. The stupendous advantages which lipid nanocarriers offer including improved drug stability and peroral bioavailability coupled with sustained drug release profile and feasibility to incorporate wide array of drugs makes it a potential candidate for pharmaceutical formulations. Furthermore, they also impart targeted drug delivery thereby widening their arena for use. Therefore, the review will encompass the details pertaining to numerous lipid nanocarriers such as nanoemulsion, solid lipid nanoparticle, nanostructured lipid carriers, and so on. These nanocarriers bear the prospective of improving the mucosal adhesion property of the drugs which ultimately upgrades its pharmacokinetic profile. The biodegradable and physiological nature of the lipid excipients used in the formulation is the key parameter and advocates for their safe use. Nevertheless, these lipid-based nanocarriers are amenable to alterations which could be rightly achieved by changing the excipients used or by modifying the process parameters. Thus, the review will systematically envisage the impending benefits and future perspectives of different lipid nanocarriers used in oral delivery of antiretroviral drugs.
Collapse
|
37
|
Rehman S, Miller A, Meagher A, Chen H, Dy G. P3.01-86 Treatment Outcomes with Reduced Frequency of Nivolumab Dosing as Second-Line Therapy in Patients with Advanced NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Nabi B, Rehman S, Khan S, Baboota S, Ali J. Ligand conjugation: An emerging platform for enhanced brain drug delivery. Brain Res Bull 2018; 142:384-393. [DOI: 10.1016/j.brainresbull.2018.08.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2018] [Revised: 07/06/2018] [Accepted: 08/02/2018] [Indexed: 10/28/2022]
|
39
|
Matsuda K, Lopez JCA, Rehman S, Misawa M, Suzuki Y, Takeuchi A, Yasumoto M, Hibino K, Roy M, Hanayama R, Ishii K. Differential interference contrast microscopy for cells using hard x-ray holography. APPLIED OPTICS 2018; 57:4795-4801. [PMID: 30118100 DOI: 10.1364/ao.57.004795] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Accepted: 05/15/2018] [Indexed: 06/08/2023]
Abstract
We propose a differential interference contrast method for cells using hard x-ray Gabor holography and knife-edge filtering in the spatial frequency domain, without relying on beam shearing. A phase object is holographically recorded and reconstructed by computer. Interference between the wavefronts of zeroth order weighted by ejπ/2 in the positive frequency region produces a dark image. Similarly, interference between the wavefronts of the zeroth order weighted by ej3π/2 in the negative frequency region produces a bright image. By adding these two intensity distributions, good quality phase-contrast images of 8-μm-diameter polystyrene beads and human HeLa cells were obtained.
Collapse
|
40
|
Farag S, Rehman S, Sains P, Baig MK, Sajid MS. Early vs delayed closure of loop defunctioning ileostomy in patients undergoing distal colorectal resections: an integrated systematic review and meta-analysis of published randomized controlled trials. Colorectal Dis 2017; 19:1050-1057. [PMID: 29028289 DOI: 10.1111/codi.13922] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2017] [Accepted: 08/31/2017] [Indexed: 02/08/2023]
Abstract
AIMS The objective of this study was to evaluate the surgical outcomes and feasibility of early loop defunctioning ileostomy closure, within 2 weeks of index surgery, in patients undergoing distal colorectal resection. METHODS A systematic review of the literature on published randomized controlled trials reporting the feasibility and outcomes on early vs delayed closure of loop defunctioning ileostomy in patients undergoing distal colorectal resection using the principles of meta-analysis on RevMan 5.4 statistical software was undertaken. RESULTS Four randomized, controlled trials on 446 patients evaluating the feasibility and outcomes on early vs delayed closure of loop defunctioning ileostomy in patients undergoing low colorectal resection were analysed. There were 176 patients in the early closure group and 270 patients in the delayed closure group. The risk of anastomotic leak [risk ratio 0.37 (CI: 0.10-1.42), P = 0.15], anastomotic stenosis [risk ratio 4.79 (CI: 0.23-98.47), P = 0.31] and postoperative complications [risk ratio 0.75 (CI: 0.48-1.16), P = 0.19] was similar in both groups. In addition, there was no significant difference between the groups with regard to the duration of operation [standardized mean difference -0.49 (CI: -01.09, -0.12), P = 0.12] and length of hospitalization [standardized mean difference -0.04 (CI: -0.25, -0.18), P = 0.75]. CONCLUSIONS Early closure of loop defunctioning ileostomy in patients undergoing distal colorectal resection is feasible with comparable outcomes to delayed closure.
Collapse
|
41
|
Rehman S, Erskine K, Pelly T, Blunstone R. Nil by Mouth Means What? Putting Evidence into Practice, A Prospective Pre-Operative Fasting Audit. Int J Surg 2017. [DOI: 10.1016/j.ijsu.2017.08.478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Rehman S, Rodway A, Qaiser R, Darwish B, Yusuf SW. A Closed Loop NCEPOD Audit of Major Amputations in a Regional Vascular Unit. Int J Surg 2017. [DOI: 10.1016/j.ijsu.2017.08.542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Watson R, Rehman S, Ali P. Stressors affecting nursing students in Pakistan. Int Nurs Rev 2017; 64:536-543. [DOI: 10.1111/inr.12392] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
44
|
Rehman S, Karmakar A, Almustafa M, Kumar N. Ketoacidosis in the diabetic neurosurgical patient: The steroid conundrum. JOURNAL OF NEUROANAESTHESIOLOGY AND CRITICAL CARE 2017. [DOI: 10.1055/s-0038-1646221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
45
|
Anwer S, Majeed A, Naveed A, Rehman S. ULTRASONOGRAPHY OF THE INTERNAL JUGULAR VEIN TO ASSESS INTRAVASCULAR STATUS IN THE ED. Arch Emerg Med 2016. [DOI: 10.1136/emermed-2016-206402.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
46
|
Weiner A, Speirs C, DeWees T, Rehman S, Molotievschi A, Velez M, Mullen D, Fergus S, Trovo M, Baggstrom M, Morgensztern D, Govindan R, Waqar S, Bradley J, Robinson C. Consolidation Chemotherapy Following Weekly Carboplatin-Paclitaxel Based Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer Is Associated With Improved Overall and Disease-Free Survival. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1739] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
47
|
Munir S, Rahman SB, Rehman S, Saba N, Torinsson Naluai Å, Agha H, Ahmad W, Mazhar K. The angiotensin-converting enzyme gene insertion polymorphism: a higher risk for psoriasis in male patients. Br J Dermatol 2016; 175:824-6. [PMID: 27061294 DOI: 10.1111/bjd.14653] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
48
|
Roach M, Rehman S, DeWees T, Bradley J, Robinson C. OC-0137: Tumour size but not location determines survival and control of lung stereotactic body radiotherapy. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)31386-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
49
|
Speirs C, LaBrash J, Mutic S, Rao Y, Rehman S, Roach M, Michalski J, Perkins S. PO-0859: Quantifying and categorizing plan rejections as a part of the clinical process improvement. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32109-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
50
|
Stevenson G, Rehman S, Draper E, Hernández-Nava E, Hunt J, Haycock JW. Combining 3D human in vitro methods for a 3Rs evaluation of novel titanium surfaces in orthopaedic applications. Biotechnol Bioeng 2016; 113:1586-99. [PMID: 26702609 PMCID: PMC4982034 DOI: 10.1002/bit.25919] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2015] [Revised: 12/21/2015] [Accepted: 12/22/2015] [Indexed: 11/06/2022]
Abstract
In this study, we report on a group of complementary human osteoblast in vitro test methods for the preclinical evaluation of 3D porous titanium surfaces. The surfaces were prepared by additive manufacturing (electron beam melting [EBM]) and plasma spraying, allowing the creation of complex lattice surface geometries. Physical properties of the surfaces were characterized by SEM and profilometry and 3D in vitro cell culture using human osteoblasts. Primary human osteoblast cells were found to elicit greater differences between titanium sample surfaces than an MG63 osteoblast-like cell line, particularly in terms of cell survival. Surface morphology was associated with higher osteoblast metabolic activity and mineralization on rougher titanium plasma spray coated surfaces than smoother surfaces. Differences in osteoblast survival and metabolic activity on titanium lattice structures were also found, despite analogous surface morphology at the cellular level. 3D confocal microscopy identified osteoblast organization within complex titanium surface geometries, adhesion, spreading, and alignment to the biomaterial strut geometries. Mineralized nodule formation throughout the lattice structures was also observed, and indicative of early markers of bone in-growth on such materials. Testing methods such as those presented are not traditionally considered by medical device manufacturers, but we suggest have value as an increasingly vital tool in efficiently translating pre-clinical studies, especially in balance with current regulatory practice, commercial demands, the 3Rs, and the relative merits of in vitro and in vivo studies. Biotechnol. Bioeng. 2016;113: 1586-1599. © 2015 The Authors. Biotechnology and Bioengineering Published by Wiley Periodicals, Inc.
Collapse
|